Reading this clinical breakthrough? See how real patients are applying these numbers in real life. See how members lowered A1C, timed Metformin ER, and optimized thyroid labs—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Diabetes, Thyroid & A1C Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Diabetes, Thyroid & A1C Space →
Official NIH NLM MEDLINE / PubMed Citation • PMID: 42969670 • DOI: 10.1177/03000605261489340

Adjunctive neodymium-doped yttrium aluminum garnet laser therapy for periodontitis in type 2 diabetes: A randomized controlled trial.

The Journal of international medical research • 2026 Nov • Vol. 54 (11) : 3000605261489340 • ISSN 1473-2300
Authors: Lijun He, Haifeng Hu, Yunhan Wang, Yue Yang
The Affiliated Hospital of Chengdu University, China.

Verbatim Formal Study Abstract

ABSTRACT

ObjectiveTo determine whether adjunctive neodymium-doped yttrium aluminum garnet laser therapy added to conventional nonsurgical periodontal therapy provides greater improvement in baseline-adjusted 6-month probing depth than conventional nonsurgical periodontal therapy alone in patients with periodontitis and type 2 diabetes mellitus.MethodsThis randomized controlled trial included 120 patients with periodontitis and type 2 diabetes mellitus. Participants were randomly assigned in a 1:1 ratio to the laser group (conventional nonsurgical periodontal therapy plus adjunctive neodymium-doped yttrium aluminum garnet laser therapy, n&#x2009;=&#x2009;60) or the control group (conventional nonsurgical periodontal therapy alone, n&#x2009;=&#x2009;60). Conventional nonsurgical periodontal therapy comprised scaling and root planing with standardized home oral-hygiene instruction and reinforcement. Periodontal and glycemic outcomes were assessed at baseline and 6 months. The primary outcome was the between-group difference in the 6-month mean probing depth, adjusted for baseline probing depth using analysis of covariance. Secondary outcomes included baseline-adjusted between-group differences in clinical attachment level, bleeding on probing-positive sites, gingival recession, glycosylated hemoglobin, and fasting plasma glucose level.ResultsBaseline characteristics were generally comparable between groups, except a modest difference in mean gingival recession. Based on the primary analysis, the baseline-adjusted 6-month mean probing depth was significantly lower in the laser group than in the control group (adjusted difference, -0.70&#x2005;mm (95% confidence interval, -0.84 to -0.56) p&#x2009;<&#x2009;0.001). Baseline-adjusted differences also favored the laser group for clinical attachment level (-0.67&#x2005;mm; 95% confidence interval, -0.79 to -0.55), bleeding on probing-positive sites (-11.3 percentage points; 95% confidence interval, -13.9 to -8.7), glycosylated hemoglobin (-0.26%; 95% confidence interval, -0.34 to -0.17), and fasting plasma glucose level (-0.62&#x2005;mmol/L; 95% confidence interval, -0.81 to -0.44) (all p&#x2009;<&#x2009;0.001). Gingival recession was slightly higher in the laser group after baseline adjustment (+0.09&#x2005;mm; 95% confidence interval, 0.03 to 0.14; p&#x2009;=&#x2009;0.004). No serious treatment-related adverse events were recorded.ConclusionsAdjunctive neodymium-doped yttrium aluminum garnet laser therapy was associated with greater short-term improvement in periodontal clinical outcomes than conventional nonsurgical periodontal therapy alone. Favorable changes in secondary glycemic outcomes were also observed; however, these results should be interpreted cautiously because cautiously because glycemic variables were secondary endpoints, and the follow-up duration was limited to 6 months.Research registration numberresearchregistry12005.

Publication Classification: Journal Article Randomized Controlled Trial
NLM MeSH Descriptors: Humans Diabetes Mellitus, Type 2 Female Male Middle Aged Lasers, Solid-State Periodontitis Treatment Outcome Glycated Hemoglobin Blood Glucose Aged